Slide 1: Q1'26 Financial Results Webcast & Call
Q1’26 Financial Results Webcast & Call May 13, 2026
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press releas
Slide 3: Bionano is among the leaders transforming pathology from analog to digital
Bionano is among the leaders transforming pathology from its analog roots into a more digital future Cytogenetics Molecular Anatomic Pathology/Clinical Pathology H&E Karyotyping FISH CMA RNA (Transcriptomics) DNA (Sequencing) Flow cytometry/Mass spectrometry staining Analog Panels Whole (hotspot/act
Slide 4: Strategic pillars
Strategic pillars Increase OGM utilization by Support & sustain the routine users by supporting installed base of routine menu expansion & improving ease OGM & VIA software users of use with VIA and Ionic adoption Improve profitability and Build support needed scalability with lower costs, for OGM r
Slide 5: Q1 2026 consumables revenue showed growth, in line with our strategy
Q1 2026 consumables revenue showed growth, in line with our strategy to focus on routine users Q1 2026 Flowcells Sold 6,994 8,178 240 456 In connection to new 21% customer sales 7,938 6,538 To existing customer base Q1 2025 Q1 2026 $6.5M $6.7M Revenue Mix $1.1 $1.6 $2.1 $1.2 Other revenue 20% Softwa
Slide 6: Upgrades to software and compute platforms to make analysis easier, faster, more accurate
Upgrades to software and compute platforms to make analysis of OGM, microarray, and NGS data easier, faster, and more accurate Software Platforms VIA 7.2 Solve 3.8.3 Broadens OGM workflow to Expands structural variant (SV) control include constitutional genetic database and improves accuracy and dis
Slide 7: Effective Jan 1, 2026, a CPT code covering OGM in genetic disorders and a 47% price increase
Effective Jan 1, 2026, a CPT code covering OGM in genetic disorders and a 47% price increase for code used for hematologic malignancies AMA CPT Code for OGM in Constitutional Genetic AMA CPT Code for OGM in Hematologic Disorders (new in 2026) Malignancies (47% price increase in 2026) Current Code #
Slide 8: On track for record number of new publications in 2026
On track for record number of new publications in 2026 with growing number of published human clinical research genomes 117 new publications in Q1 2026 1,991 human clinical research genomes published across a range of applications in Q1 2026 reaching nearly 14,700 in total 15,000 ~500 before 2021 13
Slide 9: Healthy cost structure sustains following substantial improvements over the last two years
Healthy cost structure sustains following substantial improvements over the last two years Decreased adjusted operating expenses1 Improved adjusted gross margin 1 to 49% by 6% Q/Q in Q1 2026 in Q1 2026, compared to adjusted core gross margin of 46%2 in Q1 2025 Adjusted Operating Expenses Trend ($M)
Slide 10: Q1 2026 Results
Q1 2026 Results 9.0 2025 2026 $8.0 $7.4 8.0 7.0 $6.5 $6.7 $6.7 6.0 5.0 $6.7M 8,178 49% 4.0 Q1 Flowcells Q1 Adjusted Q1 Revenue Sold Gross Margin 3.0 2.0 +4% +17% +300 bps 1.0 vs. Q1’25 vs. Q1’25 vs. Q1’25 0.0 Q1 Q2 Q3 Q4 Q1 Core Revenue ($M) $24.7M1 cash, cash equivalents, and available-for-sale sec
Slide 11: 2026 Guidance
2026 Guidance Reiterating FY’26 revenue: $30 – $33M Initiating Q2’26 revenue: $7.5 – $7.8M Cash Runway into 2027 © Cop yrig ht 202 6 Bion ano Geno mics, Inc. 11
Slide 12: Thank you.
— Thank you.
Slide 13: Statement regarding use of adjusted financial measures
Statement regarding use of adjusted financial measures Effective with the fiscal period ended March 31, 2026, the Company renamed certain of its non-GAAP financial measures. Measures previously reported as "non-GAAP gross margin," "non-GAAP operating expense," and other titles using "non-GAAP" are n
Slide 14: Reconciliation of GAAP to Adjusted Financial Measures (Unaudited)
Reconciliation of GAAP to Adjusted Financial Measures (Unaudited) Bionano Genomics, Inc. Reconciliation of GAAP to Adjusted Financial Measures (Unaudited) Three Months Ended March 31, 2026 2025 GAAP gross margin: GAAP revenue $ 6,687 $ 6,457 GAAP cost of revenue 3,435 3,519 GAAP gross profit 3,252 2